key: cord-0855213-dm8ri6xf
authors: Lau, Louis HS.; Wong, Sunny H.; Yip, Terry CF.; Wong, Grace LH.; Wong, Vincent WS.; Sung, Joseph JY.
title: Collateral Effect of COVID-19 Pandemic on Hospitalizations and Clinical Outcomes in Gastrointestinal and Liver Diseases – A Territory-wide Observational Study in Hong Kong
date: 2020-07-25
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.07.042
sha: b4231db0829f960f7912e15a4df70c52cef4f662
doc_id: 855213
cord_uid: dm8ri6xf

nan

As of July 22, 2020, there were more than 14.9 million cases and 616 thousand deaths due to Coronavirus Disease 2019 (COVID-19) worldwide. [1] Medical resources were shifted to management of infected patients. Declines in hospitalizations for acute coronary syndrome and stroke were observed. [2, 3] The world is exposed to a third wave of the pandemic. The disruption to endoscopy service is considerable, leading to potential delays in the diagnosis of cancers and management of gastrointestinal bleeding. [4, 5] We aim to evaluate the collateral effects of COVID-19 on hospitalizations and clinical outcomes in patients with gastrointestinal (GI) and liver diseases.

A territory-wide retrospective cohort study was performed involving patient-based hospital admissions in Hong Kong from January 1, 2019 to May 31, 2020. Major digestive diseases including luminal GI cancers, pancreatic-hepatobiliary cancers, benign pancreaticobiliary disorders, diseases of liver, non-infective enteritis and colitis, non-variceal and variceal upper GI bleeding (UGIB) according to their respective ICD-10 codes were included. Hospital admissions through the emergency department, or those with a length of stay more than one day were included. We defined 'season-adjusted pre-COVID19 period' from the 4 th week of January 2019 to the 4 th week of May 2019, and the 'COVID-19 period' from the 4 th week of January 2020 to the 4 th week of May 2020, during which admission data were captured. [6] The primary endpoint was the total number of hospital admissions, related to the principal or top five diagnoses of major diseases. Secondary endpoints included in-hospital mortality within the same episode of hospitalization, admission to intensive care unit (ICU), and need of operation or endoscopy (elective or emergency).

During the study period, 195,867 hospital admissions related to major digestive diseases were recorded in Hong Kong. The final analysis included 125,049 hospital admissions fulfilling inclusion and exclusion criteria.

After the first local case of COVID-19 emerged in January 2020, there was a significant decline in hospital admissions. This observation was consistent in the following weeks, until a gradual return to baseline in late March, corresponding to a relatively flat epidemic curve. [ 

Despite the reduction in hospital admissions, we did not observe significant differences in the in-hospital mortality rate (11.2% vs 11.7%, P =0.063) or the ICU admission rate (5.3% vs 5.1%, P =0.218). (Supplementary Table 2 )

The total number of surgeries decreased from 5,844 to 4,704. The magnitude was, however, similar between two periods, with 75.5% and 74.8% being major or ultra-major surgeries, respectively.

A significantly higher percentage of patients underwent emergency operations during hospitalization in the COVID-19 period (6.7% vs 8.0%, P <0.001). The elective surgery percentage was significantly lower (10.8% vs 8.7%, P <0.001). Notably, no significant difference was observed in luminal GI cancers (elective 19.5% vs 19.0%, P = 0.457; emergency 7.1% vs 7.8%, P =0.124) or pancreatic-hepatobiliary cancers (elective 10.3% vs 9.4%, P =0.208; emergency 2.0% vs 2.5%, P =0.176).

The total number of endoscopies decreased from 11,604 to 9,477, but the number of emergency endoscopies increased from 4,675 to 5,136. The percentages of patients receiving emergency endoscopies during the COVID-19 period increased from 14.0% to 18.2% (P <0.001), particularly for UGIB (30.0% vs 38.9%, P <0.001), benign pancreaticobiliary disorders (17.5% vs 24.4%, P <0.001), luminal GI cancers (6.6% vs 9.4%, P <0.001) and pancreatic-hepatobiliary cancers (7.0% vs 9.7%, P <0.001).

(Supplementary Table 2) Discussion This is a territory-wide population-based study involving more than 195,000 patient-based hospital admissions over 17 months, providing real-life data on collateral effects of COVID-19 pandemic in digestive diseases.

We found a significant reduction of 17% in hospitalizations for digestive diseases. It echoes previous studies showing a decline in hospitalizations for common cardiovascular and gastrointestinal emergencies. [2, 3, 5] However, no significant difference was demonstrated in clinical outcomes such as mortality and ICU admission rates. One possible explanation could be the relatively flat local epidemic curve, allowing the healthcare system to cope with the burden. This effort is important to allow management of non-COVID-19 patients. We may also argue that certain hospitalizations are unnecessary. A more selective admission policy may be possible.

Clinical models identifying low-risk patients who can be safely discharged from emergency department for outpatient management should be developed.

During the early phase, Hong Kong adopted policy to postpone non-essential elective services. Only emergency surgeries or endoscopies were performed for life-threatening or time-sensitive cancer-related indications. This practice was in line with international guidelines. [7, 8] Consistently, we demonstrated an overall reduction in elective surgeries except for cancers. We also observed more patients undergoing emergency endoscopies. This finding could be related to the abrupt reduction of elective services. It may also represent sicker patients with UGIB and biliary sepsis, requiring more urgent life-saving interventions.

In conclusion, hospitalizations related to digestive diseases decreased drastically during the pandemic in Hong Kong, without excessive mortality observed. More patients underwent emergency surgeries and endoscopies during hospitalization. Our findings only reflect immediate outcomes and may not be generalizable to other countries with different pandemic situations. Future studies are warranted to review the long-term effects of COVID-19 and how to minimize collateral, non-infectious adverse healthcare outcomes from the pandemic. Author names in bold designate shared co-first authorship.

We performed a territory-wide retrospective cohort study involving patients admitted to all public hospitals in Hong Kong from January 1, 2019 to May 31, 2020. Clinical parameters were retrieved through the Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority, Hong Kong. CDARS is an electronic health care database that records patients' demographics, death, diagnoses, procedures, investigation results and drug prescription from all public hospitals in Hong Kong, which represents approximately 90% of the whole 7.4-million population in Hong Kong. All patients are de-identified in CDARS to ensure confidentiality. A number of territory-wide studies were conducted by CDARS previously with the validity of data verified.

Clinical parameters including demographic data, details of hospitalization (including admission date, emergency department attendance, length of stay, episode death, admission to the intensive care unit, emergency hospital readmission within 28 days), principal and relevant diagnoses, relevant procedures and endoscopies, laboratory tests, blood products use, and concomitant drugs were retrieved and analyzed. The study was approved by the Joint Chinese University of Hong Kong -New Territories East Cluster Clinical Research Ethics Committee (CREC Reference Number: 2020.276).

We searched all patients who were admitted to public hospitals under the Hospital Authority in Hong Kong during the study period, with the principal or the top five diagnosis codes of the index hospital admission included, based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM).

The major digestive diseases included in this study were luminal GI cancers (C15 cancer of oesophagus, C16 cancer of stomach, C17 cancer of small intestine, C18 cancer of colon, C19 cancer of rectosigmoid junction, C20 cancer of rectum, C21 cancer of anus and anal canal), pancreatic and hepatobiliary cancers (C22 cancer of liver/intrahepatic ducts, C23 cancer of gallbladder, C24 cancer of biliary tract, other/NOS, C25 cancer of pancreas), benign pancreaticobiliary disorders (K80 gallstones, K81 cholecystitis, K82 other diseases of gallbladder, K83 other diseases of biliary tract, K85 acute pancreatitis, K86 other diseases of pancreas, K87 gallbladder/biliary/pancreatic disorder, other diseases), diseases of liver (K70 alcoholic liver disease, K71 toxic liver disease, K72 hepatic failure, NEC, K73 chronic hepatitis, NEC, K74 fibrosis and cirrhosis of liver, K75 other inflammatory liver diseases, K76 other diseases of liver, K77 liver disorders in other diseases), non-infective enteritis and colitis (K50 Crohn's disease, K51 ulcerative colitis, K52 other non-infective GE/colitis), non-variceal and variceal upper GI bleeding (K25 GU, K26 DU, K27 PU, site unspecified, K28 gastrojejunal ulcer, K92.0 hematemesis, K92.1 melaena, K92.2 GI bleeding, unspecified, I85 oesophageal varices, I86.4 gastric varices, I98.2 oesophageal varices in other diseases, I98.3 oesophageal varices with bleeding in diseases). They were the common and potentially life-threatening diseases, including different spectrum of benign (cholangitis, pancreatitis, GI bleeding, inflammatory bowel disease, liver failure and cirrhosis) and malignant conditions (luminal, pancreatico-biliary and hepatic cancers), which represented the majority of hospitalization in daily clinical practice.

We further excluded patient-based hospital admissions without emergency department attendance and the length of stay in hospital equal to or shorter than one day. It was because these entries largely represented day ward admissions related to blood product transfusion, parental drug/chemotherapy administration or simple diagnostic procedures. As a result, we included patients admitted to hospitals during January 1, 2019 to May 31, 2020, either with emergency department attendance or with length of stay for more than one day, related to the above principal or top five diagnoses of major GI diseases for subsequent analysis.

The primary endpoint was total number of index hospital admissions during the study period, related to the principal or top five diagnoses of major digestive diseases mentioned above. The secondary endpoints included in-hospital mortality within the same episode of hospitalization, admission to the intensive care unit (ICU), and the need of operation or endoscopy (elective or emergency).

In Hong Kong, there were 2,020 confirmed cases of COVID-19 and 14 deaths as of July 22, 2020. The first local case was diagnosed on January 22, 2020 (i.e. January 2020 week 4). On January 24, the 'emergency response level' of the preparedness and response plan against infectious disease outbreak was activated, followed by closure of border-control points. In early February 2020, the Hospital Authority announced the policy to postpone non-essential elective surgeries and endoscopies. Emergency services and essential surgeries for cancer treatment were maintained. In this study, we defined the pre-COVID19 period to be January 2019 week 1 to January 2020 week 3, and the COVID-19 period to be January 2020 week 4 to May 2020 week 4.

Data were analyzed using International Business Machines Corporation Statistical Product and Service Solutions version 25.0 (IBM SPSS, Inc., Chicago, Illinois), and R software (4.0.0; R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were expressed in mean ± standard deviation or median (interquartile range) as appropriate, while categorical variables were presented as frequency (percentage). Wilcoxon signed-rank test was used to compare number of hospital admission among hospitalized patients in the time periods of January 2019 week 4 to May 2019 week 4 (season-adjusted pre-COVID-19 period) versus January 2020 week 4 to May 2020 week 4 (COVID-19 period); Mann-Whitney test was used to compare the number of hospital admission, and Chi-square test was used to compare the mortality rate, usage of ICU, and rate of elective and emergency operations; the possible correlation between the two time periods was not accounted for by Mann-Whitney and Chi-square tests in the comparison. Interrupted time series analysis by piecewise linear regression was performed to examine the trend in hospitalization before and after the COVID-19 outbreak in Hong Kong. Autocorrelation of the residuals of the fitted models were checked by autocorrelation functions, partial autocorrelation functions, and Durbin-Watson tests. For detected autocorrelation, regression standard errors were adjusted for autocorrelation at the identified order using Newey-West covariance matrix estimators. All statistical tests were two-sided. Statistical significance was taken as P <0.05. ^ The proportion of mortality, ICU admission, elective and emergency surgery, elective and emergency endoscopy between the season-adjusted pre-COVID-19 period and the COVID-19 period were compared by Chi-square test. The possible correlation between the two time periods was not accounted for in the comparison.

A Novel Coronavirus from Patients with Pneumonia in China

Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy

Collateral Effect of Covid-19 on Stroke Evaluation in the United States

Impacts of COVID-19 Pandemic on Gastrointestinal Endoscopy Volume and Diagnosis of Gastric and Colorectal Cancers: A Population-based Study

Decline in acute upper gastrointestinal bleeding during Covid-19 pandemic after lockdown in Austria

AGA Institute Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic